Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of…

Overview of attention for article published in Frontiers in oncology, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (65th percentile)

So far, Dimensions has found 2 publications that cite this research output.

Article in Hematological Oncology (May 2024)

Article in Haematologica (July 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.